Results 221 to 230 of about 390,786 (264)

Engineering Tertiary Lymphoid Structures: Nanomedicine, Bioengineering, and Biomaterials for Precision Immunotherapy

Advanced NanoBiomed Research, EarlyView.
This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley   +1 more source

Rapidly evolving therapeutic advances for classical <i>EGFR</i>-mutant NSCLC. [PDF]

Front Oncol
Pan K, Ramalingam SS.
europepmc   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Does different surgical approaches affect tolerance to postoperative adjuvant chemotherapy in early-stage upper gastric cancer? [PDF]

Front Surg
Zuo S, Zhang Y, Liao X.
europepmc   +1 more source

Bacterial Pigments as Potential Antitumor Agents Against Gastrointestinal Cancers: A Comprehensive Systematic Review

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Gastrointestinal cancers (GICs) constitute one of the leading causes of cancer‐related morbidity and mortality worldwide. Despite currently available therapeutic strategies, new approaches and procedures are needed for their prevention and treatment.
Raúl Vergara, Ricardo F. S. Pereira, Carla C. C. R. de Carvalho, Jose Prados, Consolación Melguizo, Raul Ortiz   +5 more
wiley   +1 more source

Prognostic Value of STAS, Lymph Node Metastasis, and VPI in NSCLC ≤ 4 cm Treated with Lobectomy. [PDF]

J Clin Med
Zeynelgil E, Koçanoğlu A, Arıkök AT, Karakaya S, Kavak EE, Eren T.   +5 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment. [PDF]

Eur J Breast Health
Şenocak Taşçı E, Sönmez Ö, Oyan Uluç B, Korkmaz T, Yıldız İ, Bozkurt M, Can O, Arıcan A, İçten GE, Uras C, Eralp Y.   +10 more
europepmc   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

Efficacy of Adjuvant Chemotherapy for T1-2 Stage III Colorectal Cancer. [PDF]

Cancers (Basel)
Maeda H, Oba K, Kashiwabara K, Aoyama T, Mayanagi S, Kanda M, Honda M, Muto M, Sakamoto J, Yamagishi H, Yoshikawa T.   +10 more
europepmc   +1 more source